P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2021
Source ID
10.1016/j.annonc.2021.05.118

Entities

People

  • A. Negro
  • B. Evans
  • D. Ruscica
  • Daniela Molena
  • E. Van Cutsem
  • J. Tabernero
  • K. Muro
  • S. Al-batran
  • S. Robbins
  • W. Hyung
  • Y. Janjigian
  • Z. Wainberg

Organizations

  • AstraZeneca
  • Basilea Pharmaceutica
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • National Cancer Institute
  • Pfizer
  • United States Department of Defense